TwinStrand raises $16M Series A led by Madrona to commercialize Duplex Sequencing with 10,000× greater accuracy
TwinStrand Biosciences raised $16 million in a Series A led by Madrona to commercialize its Duplex Sequencing technology, which it says finds rare genetic variants with up to 10,000× greater accuracy than standard methods and could enable earlier cancer detection and faster carcinogen identification.